Pure MHC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases, and allergy.
Pure MHC Headquarter Location
7500 Rialto Blvd Bldg. 2, Ste. 260
Austin, Texas, 78735,
Predict your next investment
The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.
Expert Collections containing Pure MHC
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pure MHC is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
OKLAHOMA CITY, Okla. /Massachusetts Newswire - National News/ -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
The post Myrio Therapeutics and Pure MHC Announce Collaboration to Research and Develop Novel, Targeted Antibody-Based Cancer Therapies appeared first on Massachusetts Newswire.